# US 2025/0325580 A1 · Methods and systems for inhibiting foreign-body responses in diabetic patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325580 A1
- Document ID: US20250325580A1
- Status: Published application
- Kind: A1
- Application number: 19/254,702
- Filed: 2025-06-30
- Published: 2025-10-23
- Earliest claimed: 2013-10-22
- Assignees: Medtronic MiniMed, Inc.
- Applicants: Medtronic Minimed, Inc.
- Inventors: Sarnath Chattaraj; Kiem H. Dang; Hsi Chung Fusselman; Poonam S. Gulati; Lance P. Hoffman; Guangping Zhang
- Web page: https://patentgrep.com/patent/US20250325580A1

## CPC

- A61K 31/727: Heparin; Heparan
- A61K 38/28: Insulins
- A61L 29/08: Materials for coatings
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61M 5/14248: {of the skin patch type}
- A61M 5/158: Needles {for infusions; Accessories therefor, e.g. for inserting infusion needles, or for holding them on the body}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/50: for increasing or potentiating the activity of insulin
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2300/236: Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/42: Anti-thrombotic agents, anticoagulants, anti-platelet agents
- A61M 5/16827: {controlling delivery of multiple fluids, e.g. sequencing, mixing or via separate flow-paths (infusion of multiple fluids without using a controller A61M5/1407)}
- A61M 5/16836: {by sensing tissue properties at the infusion site, e.g. for detecting infiltration}
- A61M 2005/1586: {Holding accessories for holding infusion needles on the body}
- A61M 2205/0205: Materials having antiseptic or antimicrobial properties, e.g. silver compounds, rubber with sterilising agent
- A61M 2205/0238: the material being a coating or protective layer
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and devices are provided for reducing a diabetic patient's foreign body immune response, including infusion site-loss and/or occlusion. Such foreign body responses are associated with the treatment of the diabetic patient where the treatment requires subcutaneous implantation of a foreign body, such as a cannula or catheter. In certain embodiments of the invention, a response-inhibiting agent is administered to a patient at the site of cannula/catheter insertion, thereby facilitating delivery of insulin to the diabetic patient and mitigating site-loss and/or occlusion over a period of time.

## Claims

### Claim 1

A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising:
a medication reservoir comprising an insulin solution;
a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;
a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion;
a site loss mitigating agent comprising rapamycin that inhibits at least one of: coagulation at the single site of infusion, inflammation at the single site of infusion, and encapsulation of the cannula at the single site of infusion.

### Claim 2 (depends on 1)

The system of claim 1, wherein the site loss mitigating agent is:
(a) disposed within a depot and adapted to contact the insulin solution as the insulin solution flows from the medication reservoir to the single site of infusion; and/or
(b) pre- or in-situ mixed with insulin and/or
(c) which coats the cannula.

### Claim 3 (depends on 2)

The system of claim 2, wherein the depot includes a membrane and/or a filter and/or a sponge and/or a polymeric material and/or a metal comprising rapamycin.

### Claim 4 (depends on 1)

The system of claim 1, wherein the system further comprises dextran adapted to contact the insulin solution.

### Claim 5 (depends on 4)

The system of claim 4, wherein the dextran is administered to the patient at a concentration between 0.0005 and 0.4 mg/kg/day.

### Claim 6 (depends on 1)

The system of claim 1, wherein the period of time is at least 4, 5, 6, 7, 8 or 9 days.

### Claim 7 (depends on 1)

The system of claim 1, wherein the site loss mitigating agent:
(a) coats the fluid path including cannula;
(b) coats a septum and/or the inner surface within the medication reservoir; or
(c) is disposed within a transdermal patch; and/or
(d) coats the cannula, internally or externally or both.

### Claim 8

A system for delivering insulin to a diabetic patient at a single site of infusion over a period of time, the system comprising:
a medication reservoir comprising an insulin solution;
a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;
a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion; and
a rapamycin composition that inhibits inflammation at the single site of infusion; and wherein the system delivers an amount of rapamycin sufficient to inhibit inflammation at the single site of infusion for a period of time of at least 4 days.

### Claim 9 (depends on 8)

The system of claim 8, wherein the system further delivers rapamycin according to at least one delivery profile including:
(a) an immediate release profile wherein the rapamycin is administered to the patient from 0 to 6 hours following insertion of the cannula; and
(b) an extended release profile wherein the response-inhibiting agent is administered to the patient for at least 48 hours following insertion of the cannula.

### Claim 10 (depends on 8)

The system of claim 8, wherein the system further comprises dextran adapted to contact the insulin solution.

### Claim 11 (depends on 10)

The system of claim 10, wherein the dextran is administered to the patient at a concentration between 0.0005 and 0.4 mg/kg/day.

### Claim 12

A method for mitigating a foreign body response in a diabetic patient receiving insulin at a single infusion site over a time period of at least three days, the method comprising:
administering a site loss mitigating agent comprising rapamycin in combination with insulin at the single infusion site, wherein the site loss mitigating agent mitigates at least one of: coagulation at the single infusion site, inflammation at the single infusion site, anti proliferation and encapsulation of the cannula at the single infusion site, thereby inhibiting a foreign body response in a diabetic patient.

### Claim 13 (depends on 12)

The method of claim 12, wherein the time period is at least 4, 5, 6, 7, 8, 9, 10, 11 or 12 days.

### Claim 14 (depends on 12)

The method of claim 12, wherein the response-inhibiting agent is combined with the insulin prior to delivery of the insulin.

### Claim 15 (depends on 12)

The method of claim 12, wherein the response-inhibiting agent:
is disposed in a depot adapted to contact an insulin solution as the insulin solution flows from a medication reservoir to the single infusion site;
is disposed on the cannula;
is disposed in a transdermal patch that secures the infusion set to the patient; and/or
is disposed in a drug-coated septum and/or inside surface within a reservoir of an insulin pump.

### Claim 16 (depends on 12)

The method of claim 12, further including administering dextran, tacrolimus, or combination thereof.

### Claim 17

A method for delivering insulin to a diabetic patient at a single site of infusion over a period of at least four days, the method comprising infusing the insulin at the single site of infusion using a system comprising:
a medication reservoir comprising an insulin solution;
a cannula adapted for subcutaneous insertion into a tissue of a diabetic patient at the single site of infusion;
a fluid conduit in operable contact with the medication reservoir and the cannula and adapted to deliver insulin from the medication reservoir to the single site of infusion;
a site loss mitigating agent comprising rapamycin that inhibits at least one of: coagulation at the single site of infusion, inflammation at the single site of infusion, proliferation and encapsulation of the cannula at the single site of infusion;
so that insulin is delivered to the diabetic patient.

### Claim 18 (depends on 17)

The method of claim 17, wherein the rapamycin is disposed within a depot and adapted to contact the insulin solution as the insulin solution flows from the medication reservoir to the single site of infusion.

### Claim 19 (depends on 17)

The method of claim 17, wherein the rapamycin that inhibits inflammation at the single site of infusion.

### Claim 20 (depends on 19)

The method of claim 19, wherein the rapamycin that inhibits inflammation at the single site of infusion for at least 4 days.
